Imprimis Pharmaceuticals will offer a low-cost dry eye treatment intended as an alternative to Allergan’s Restasis, the company announced.
The company will offer the compounded cyclosporine-based formulation in a multi-use, preservative-free bottle, with prescriptions for the patent pending formulation initially filled for 99 cents and refills starting at $79 per month, according to a company press release.
Mark Baum, Imprimis CEO, said in the release, “Topical cyclosporine, which is an off-patent and inexpensive drug, can cost more than $5,000 per year when it is purchased in the
Uncategorized